LYMPHOMAS

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.

A phase 2 study reveals promising results for zanubrutinib combined with R-CHOP in treating untreated diffuse large B-cell lymphoma patients.

GLPG5101 shows promising efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma, achieving high response rates and rapid manufacturing.

A targeted therapy-first approach shows promise in reducing chemotherapy needs for newly diagnosed large B-cell lymphoma patients, maintaining high response rates.

Epcoritamab combined with rituximab and lenalidomide shows remarkable efficacy in treating relapsed follicular lymphoma, setting a new standard of care.

Epcoritamab combined with R-mini-CHOP shows promising efficacy and safety in elderly DLBCL patients, achieving high response rates and durable remissions.

Odronextamab shows promising efficacy in treating untreated DLBCL, achieving high response rates when combined with CHOP chemotherapy in early trials.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

Sonrotoclax gains FDA priority review for relapsed mantle cell lymphoma, showcasing promising efficacy and safety in challenging patient populations.

The JULIET trial reveals long-term efficacy and safety of CAR-T therapy tisagenlecleucel in relapsed/refractory large B-cell lymphoma patients.

The FDA approves epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a new second-line treatment option.

MB-105 receives FDA RMAT designation, advancing treatment options for relapsed T-cell lymphoma and highlighting its promising clinical potential.

The FDA clears the way for a pivotal phase 3 trial of lacutamab, promising new hope for patients with cutaneous T-cell lymphomas.

Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell lymphoma, with durable responses reported.

A phase 1 trial reveals that combining radiotherapy with immunotherapy enhances response rates in B-cell lymphomas while maintaining manageable safety profiles.

The identification of biomarkers in frontline diffuse large B-cell lymphoma (DLBCL) is ramping up with interest in exploring cell of origin.

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data and innovative technology.

Sonrotoclax receives FDA breakthrough designation, promising new hope for patients with relapsed mantle cell lymphoma after standard treatments fail.

New findings from the SUNMO study highlight the promising efficacy and safety of Mosun-Pola for treating relapsed large B-cell lymphoma, offering a chemotherapy-free option.

A phase 2 study reveals low-dose nivolumab and lenalidomide as a promising, safe, chemotherapy-free treatment for classical Hodgkin lymphoma.

CAR T-cell therapy for DLBCL shows promise in outpatient settings, reducing hospital stays and improving patient quality of life while managing toxicities effectively.

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Discover the latest advancements in lymphoma treatment, including innovative therapies and personalized medicine, enhancing patient outcomes and quality of life.